<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01483183</url>
  </required_header>
  <id_info>
    <org_study_id>269-11-215</org_study_id>
    <nct_id>NCT01483183</nct_id>
  </id_info>
  <brief_title>Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation</brief_title>
  <acronym>CADENCE 215</acronym>
  <official_title>A Multi-center, Parallel-group, Double-blind, Placebo-controlled, Randomized, Ascending Dose Trial to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Infusions of OPC-108459 Administered to Subjects With Paroxysmal and Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of Part 1 of this study is to determine the maximally tolerated dose of
      OPC-108459 in patients with paroxysmal and persistent atrial fibrillation (AF).

      The purpose of Part 2 of this study is to determine potential efficacy of dose(s) of
      OPC-108459 for the treatment of paroxysmal and persistent atrial fibrillation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will test the pharmacokinetic and pharmacodynamic characteristics of ascending
      doses of OPC-108459 in separate populations of paroxysmal and persistent AF subjects.

      The trial will consist of two parts. Each part will evaluate two populations of subjects
      presenting for cardioversion in a hospital setting.

      Cohorts of paroxysmal and persistent subjects may have their dose increased independently.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrollment Difficulty
  </why_stopped>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Maximum (Peak) Plasma Concentration (Cmax)</measure>
    <time_frame>24 hours</time_frame>
    <description>OPC-108459 was administered as a 10-minute constant rate IV infusion. Blood samples were collected pre-dose (within 45 minutes of dosing), at the end of infusion and 0.5, 1, 2, 4, 8 and 24 hours post start of infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Area Under the Concentration-time Curve From Time 0 to Time of the Last Measurable Concentration (AUCÏ„)</measure>
    <time_frame>24 hours</time_frame>
    <description>OPC-108459 was administered as a 10-minute constant rate IV infusion. Blood samples were collected pre-dose (within 45 minutes of dosing), at the end of infusion and 0.5, 1, 2, 4, 8 and 24 hours post infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1:Maximal Change From Baseline in QT Interval Corrected for Heart Rate Using the Fridericia Formula (QTcF) Within 24 Hour Infusion</measure>
    <time_frame>24 hours</time_frame>
    <description>12-lead Holter monitors were placed on all participants within 45 minutes prior to dosing. Post dose measurements were made at 2, 4, 6, 8, 10, 20, 30, and 40 minutes and 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose. To achieve consistent recording, Holter sampling will be recorded with the participant recumbent and at rest for at least 10 minutes prior to collection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Maximal Change From Baseline in Ventricular Rate Within 24 Hour Infusion</measure>
    <time_frame>24 hours</time_frame>
    <description>12-lead Holter monitors were placed on all participants within 45 minutes prior to dosing. Post dose measurements were made at 2, 4, 6, 8, 10, 20, 30, and 40 minutes and 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose. To achieve consistent recording, Holter sampling will be recorded with the participant recumbent and at rest for at least 10 minutes prior to collection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Maximal Change From Baseline in Blood Pressure Within 24 Hour Infusion</measure>
    <time_frame>24 hours</time_frame>
    <description>Maximum change from baseline in diastolic and systolic blood pressure(BP) collected during vital sign measurements in the 24-hour postdose interval. Participants must be hemodynamically stable defined as a screening systolic blood pressure between 90 to 160 mmHg, diastolic &lt;100 mmHg. BP was measured after at least 3 minutes in the supine position. BP was measured at predose (within 45 minutes of dosing); 3 and 7 minutes and approximately 1, 4, 8, 12, and 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2/1 Infusion: Cmax</measure>
    <time_frame>24 hours</time_frame>
    <description>The trial was terminated after Part 1 enrollment completed. All analyses described in this document were performed on Part 1 data. However, Part 2 was not conducted and therefore is not included in this document.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2/2 Infusions: Cmax</measure>
    <time_frame>24 hours</time_frame>
    <description>The trial was terminated after Part 1 enrollment completed. All analyses described in this document were performed on Part 1 data. However, Part 2 was not conducted and therefore is not included in this document.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2/1 Infusion: AUCt</measure>
    <time_frame>24 hours</time_frame>
    <description>The trial was terminated after Part 1 enrollment completed. All analyses described in this document were performed on Part 1 data. However, Part 2 was not conducted and therefore is not included in this document.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2/2 Infusions: AUCt</measure>
    <time_frame>24 hours</time_frame>
    <description>The trial was terminated after Part 1 enrollment completed. All analyses described in this document were performed on Part 1 data. However, Part 2 was not conducted and therefore is not included in this document.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: QTcF</measure>
    <time_frame>24 hours</time_frame>
    <description>The trial was terminated after Part 1 enrollment completed. All analyses described in this document were performed on Part 1 data. However, Part 2 was not conducted and therefore is not included in this document.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Ventricular Rate</measure>
    <time_frame>24 hours</time_frame>
    <description>The trial was terminated after Part 1 enrollment completed. All analyses described in this document were performed on Part 1 data. However, Part 2 was not conducted and therefore is not included in this document.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Diastolic and Systolic Blood Pressure</measure>
    <time_frame>24 hours</time_frame>
    <description>The trial was terminated after Part 1 enrollment completed. All analyses described in this document were performed on Part 1 data. However, Part 2 was not conducted and therefore is not included in this document.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Percentage of Subjects With Normal Sinus Rhythm (NSR)</measure>
    <time_frame>24 hours</time_frame>
    <description>The trial was terminated after Part 1 enrollment completed. All analyses described in this document were performed on Part 1 data. However, Part 2 was not conducted and therefore is not included in this document.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Percentage of Participants With NSR</measure>
    <time_frame>30 minutes</time_frame>
    <description>Percent of participants with NSR, defined as NSR for at least 1 minute within 30 minutes of the end of OPC-108459 infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Time to NSR</measure>
    <time_frame>24 hours</time_frame>
    <description>The trial was terminated after Part 1 enrollment completed. All analyses described in this document were performed on Part 1 data. However, Part 2 was not conducted and therefore is not included in this document.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Duration of NSR</measure>
    <time_frame>24 hours</time_frame>
    <description>The trial was terminated after Part 1 enrollment completed. All analyses described in this document were performed on Part 1 data. However, Part 2 was not conducted and therefore is not included in this document.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Duration of NSR</measure>
    <time_frame>168 hours</time_frame>
    <description>The trial was terminated after Part 1 enrollment completed. All analyses described in this document were performed on Part 1 data. However, Part 2 was not conducted and therefore is not included in this document.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Persistent or Paroxysmal AF Part 1: OPC-108459</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To safely meet each of the following Cmax targets: 1.0-10.0 Âµg/mL. There will be 9 cohorts in all: 1.0, 1.6, 2.4, 3.6, 5.4, 7.0, 8.0, 9.0, and 10.0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Persistent or Paroxysmal AF Part 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Persistent or Paroxysmal AF Part 2: OPC-108459</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose to safely meet target concentration from Part 1, if subject fails to convert to sinus rhythm within 10 minutes, second dose will be administered to achieve 25% increase when compared to first infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Part 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC-108459</intervention_name>
    <description>Part 1: single dose OPC-108459, 10-minute constant rate IV infusion to achieve specified Cmax target
Part 2: single dose OPC-108459, 10-minute constant rate IV infusion to achieve Cmax target concentration from Part 1; if failure to convert to sinus rhythm, second dose OPC-108459 administered, 10-minute constant rate IV infusion to achieve target concentration from Part 1</description>
    <arm_group_label>Persistent or Paroxysmal AF Part 1: OPC-108459</arm_group_label>
    <arm_group_label>Persistent or Paroxysmal AF Part 2: OPC-108459</arm_group_label>
    <arm_group_label>Placebo Part 2</arm_group_label>
    <other_name>269-11-215</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo dose, 10-minute constant rate IV infusion</description>
    <arm_group_label>Persistent or Paroxysmal AF Part 1: Placebo</arm_group_label>
    <arm_group_label>Placebo Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with paroxysmal atrial fibrillation (AF) (recent or new onset) or subjects
             with persistent AF at the time of randomization

          -  Subjects who are hemodynamically stable

          -  Subjects with a low risk of thromboembolic potential

          -  Subjects who are willing to comply with the reproductive precautions

        Exclusion Criteria:

        Subjects with:

          -  History of long QT syndrome, Torsade de Pointes or an uncorrected QT interval of &gt; 450
             ms

          -  History of myocardial infarction within 6 months of screening

          -  Acute coronary syndrome, angina or active myocardial ischemia diagnosed by ECG, or
             other imaging within 6 months of screening

          -  History of ventricular tachycardia, fibrillation, or resuscitated cardiac arrest

          -  History of clinically significant congenital heart disease

          -  Presence of severe aortic or mitral stenosis, aortic or mitral regurgitation, atrial
             septal defect, or other conditions leading to AF

          -  Diagnosis of heart failure NYHA Class II-IV or with an ejection fraction &lt;40% (Part 1
             only)

          -  Diagnosis of heart failure NYHA Class IV or NYHA I, II, or III with an ejection
             fraction &lt;35% (Part 2 only)

          -  Concomitant treatment with class I or III anti-arrhythmics agents unless the
             medication was discontinued more than 5 half-lives before dosing

          -  History of seizures

          -  Diagnosis of atrial flutter

          -  Diagnosis of stroke, TIA (transient ischemic attack), or any transient neurological
             deficit within 1 year of screening or known carotid artery stenosis of &gt;50%

          -  Cardiac surgery within 3 months of screening

          -  Bradycardia (&lt; 50 bpm) or sick sinus syndrome, unless controlled by a pacemaker

          -  Current reversible cause of AF

          -  Wolff-Parkinson-White syndrome

          -  Any congenital abnormality, severe valve disease

          -  Subjects who have taken another investigational product within 30 days of dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Johnson City</city>
        <state>New York</state>
        <zip>13790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13953</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22291</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Pirna</city>
        <zip>01796</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>San Fermo</city>
        <state>Como</state>
        <zip>22100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Ancona</city>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Cremona</city>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Fuenlabrada</city>
        <state>Madrid</state>
        <zip>28942</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08970</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Chertsey</city>
        <state>Surrey</state>
        <zip>KT160PZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Denmark</country>
  </removed_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2011</study_first_submitted>
  <study_first_submitted_qc>November 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2011</study_first_posted>
  <results_first_submitted>October 4, 2016</results_first_submitted>
  <results_first_submitted_qc>February 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 10, 2017</results_first_posted>
  <last_update_submitted>February 24, 2017</last_update_submitted>
  <last_update_submitted_qc>February 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Paroxysmal Atrial fibrillation</keyword>
  <keyword>Persistent Atrial fibrillation</keyword>
  <keyword>A-fib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This trial was conducted in 40 participants at 10 trial sites in the following 3 countries: Germany, Spain, and the United States.</recruitment_details>
      <pre_assignment_details>The trial consists of two parts (Part 1 and Part 2). Each part evaluates two populations of participants for cardioversion in a hospital setting; one diagnosed with paroxysmal atrial fibrillation (AF) and the second diagnosed with persistent AF. However, Part 2 was not conducted and therefore is not included in this document.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Paroxysmal AF - OPC-108459 0.26 mg/kg</title>
          <description>Participants received a single dose of OPC-108459 0.26 milligram per kilogram (mg/kg), 10-minute constant rate intravenous (IV) infusion to achieve specified Cmax target.</description>
        </group>
        <group group_id="P2">
          <title>Paroxysmal AF - OPC-108459 0.40 mg/kg</title>
          <description>Participants received a single dose of OPC-108459 0.40 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
        </group>
        <group group_id="P3">
          <title>Paroxysmal AF - OPC-108459 1.00 mg/kg</title>
          <description>Participants received a single dose of OPC-108459 1.00 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
        </group>
        <group group_id="P4">
          <title>Paroxysmal AF - Placebo</title>
          <description>Participants received placebo dose 10-minute constant rate IV infusion.</description>
        </group>
        <group group_id="P5">
          <title>Persistent AF - OPC-108459 0.26 mg/kg</title>
          <description>Participants received a single dose of OPC-108459 0.26 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
        </group>
        <group group_id="P6">
          <title>Persistent AF - OPC-108459 0.40 mg/kg</title>
          <description>Participants received a single dose of OPC-108459 0.40 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
        </group>
        <group group_id="P7">
          <title>Persistent AF - OPC-108459 0.60 mg/kg</title>
          <description>Participants received a single dose of OPC-108459 0.60 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
        </group>
        <group group_id="P8">
          <title>Persistent AF - OPC-108459 1.35 mg/kg</title>
          <description>Participants received a single dose of OPC-108459 1.35 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
        </group>
        <group group_id="P9">
          <title>Persistent AF - OPC-108459 1.55 mg/kg</title>
          <description>Participants received a single dose of OPC-108459 1.55 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
        </group>
        <group group_id="P10">
          <title>Persistent AF - Placebo</title>
          <description>Participants received a single dose of placebo, 10-minute constant rate IV infusion.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Paroxysmal AF - OPC-108459 0.26 mg/kg</title>
          <description>Participants had received a single dose of OPC-108459 0.26 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
        </group>
        <group group_id="B2">
          <title>Paroxysmal AF - OPC-108459 0.40 mg/kg</title>
          <description>Participants had received a single dose of OPC-108459 0.40 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
        </group>
        <group group_id="B3">
          <title>Paroxysmal AF - OPC-108459 1.00 mg/kg</title>
          <description>Participants had received a single dose of OPC-108459 1.00 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
        </group>
        <group group_id="B4">
          <title>Paroxysmal AF - Placebo</title>
          <description>Participants had received placebo dose 10-minute constant rate IV infusion.</description>
        </group>
        <group group_id="B5">
          <title>Persistent AF - OPC-108459 0.26 mg/kg</title>
          <description>Participants had received a single dose of OPC-108459 0.26 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
        </group>
        <group group_id="B6">
          <title>Persistent AF - OPC-108459 0.40 mg/kg</title>
          <description>Participants had received a single dose of OPC-108459 0.40 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
        </group>
        <group group_id="B7">
          <title>Persistent AF - OPC-108459 0.60 mg/kg</title>
          <description>Participants had received a single dose of OPC-108459 0.60 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
        </group>
        <group group_id="B8">
          <title>Persistent AF - OPC-108459 1.35 mg/kg</title>
          <description>Participants had received a single dose of OPC-108459 1.35 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
        </group>
        <group group_id="B9">
          <title>Persistent AF - OPC-108459 1.55 mg/kg</title>
          <description>Participants had received a single dose of OPC-108459 1.55 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
        </group>
        <group group_id="B10">
          <title>Persistent AF - Placebo</title>
          <description>Participants had received a single dose of placebo, 10-minute constant rate IV infusion.</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="4"/>
            <count group_id="B6" value="4"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="4"/>
            <count group_id="B9" value="4"/>
            <count group_id="B10" value="5"/>
            <count group_id="B11" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.3" spread="19.0"/>
                    <measurement group_id="B2" value="75.0" spread="0.0"/>
                    <measurement group_id="B3" value="68.4" spread="9.1"/>
                    <measurement group_id="B4" value="61.0" spread="14.1"/>
                    <measurement group_id="B5" value="65.0" spread="5.7"/>
                    <measurement group_id="B6" value="75.0" spread="10.1"/>
                    <measurement group_id="B7" value="63.5" spread="14.7"/>
                    <measurement group_id="B8" value="64.8" spread="12.9"/>
                    <measurement group_id="B9" value="64.3" spread="7.7"/>
                    <measurement group_id="B10" value="70.4" spread="8.8"/>
                    <measurement group_id="B11" value="66.6" spread="11.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Maximum (Peak) Plasma Concentration (Cmax)</title>
        <description>OPC-108459 was administered as a 10-minute constant rate IV infusion. Blood samples were collected pre-dose (within 45 minutes of dosing), at the end of infusion and 0.5, 1, 2, 4, 8 and 24 hours post start of infusion.</description>
        <time_frame>24 hours</time_frame>
        <population>PK analysis dataset included all participants who had concentration time profiles consistent with proper intravenous infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxysmal AF - OPC-108459 0.26 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 0.26 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O2">
            <title>Paroxysmal AF - OPC-108459 0.40 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 0.40 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O3">
            <title>Paroxysmal AF - OPC-108459 1.00 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 1.00 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O4">
            <title>Persistent AF - OPC-108459 0.26 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 0.26 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O5">
            <title>Persistent AF - OPC-108459 0.40 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 0.40 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O6">
            <title>Persistent AF - OPC-108459 0.60 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 0.60 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O7">
            <title>Persistent AF - OPC-108459 1.35 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 1.35 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O8">
            <title>Persistent AF - OPC-108459 1.55 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 1.55 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Maximum (Peak) Plasma Concentration (Cmax)</title>
          <description>OPC-108459 was administered as a 10-minute constant rate IV infusion. Blood samples were collected pre-dose (within 45 minutes of dosing), at the end of infusion and 0.5, 1, 2, 4, 8 and 24 hours post start of infusion.</description>
          <population>PK analysis dataset included all participants who had concentration time profiles consistent with proper intravenous infusion.</population>
          <units>Î¼g/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" spread="0.358"/>
                    <measurement group_id="O2" value="1.49">Due to only 1 participant with evaluable data.</measurement>
                    <measurement group_id="O3" value="2.96" spread="0.787"/>
                    <measurement group_id="O4" value="1.45" spread="1.43"/>
                    <measurement group_id="O5" value="1.54" spread="0.538"/>
                    <measurement group_id="O6" value="1.62" spread="1.07"/>
                    <measurement group_id="O7" value="NA">The data was not evaluable as the PK was collected from the same line as the infusion. Hence, there is no data available.</measurement>
                    <measurement group_id="O8" value="5.14" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Area Under the Concentration-time Curve From Time 0 to Time of the Last Measurable Concentration (AUCÏ„)</title>
        <description>OPC-108459 was administered as a 10-minute constant rate IV infusion. Blood samples were collected pre-dose (within 45 minutes of dosing), at the end of infusion and 0.5, 1, 2, 4, 8 and 24 hours post infusion.</description>
        <time_frame>24 hours</time_frame>
        <population>PK analysis dataset included all participants who had concentration time profiles consistent with proper intravenous infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxysmal AF - OPC-108459 0.26 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 0.26 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O2">
            <title>Paroxysmal AF - OPC-108459 0.40 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 0.40 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O3">
            <title>Paroxysmal AF - OPC-108459 1.00 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 1.00 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O4">
            <title>Persistent AF - OPC-108459 0.26 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 0.26 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O5">
            <title>Persistent AF - OPC-108459 0.40 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 0.40 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O6">
            <title>Persistent AF - OPC-108459 0.60 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 0.60 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O7">
            <title>Persistent AF - OPC-108459 1.35 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 1.35 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O8">
            <title>Persistent AF - OPC-108459 1.55 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 1.55 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Area Under the Concentration-time Curve From Time 0 to Time of the Last Measurable Concentration (AUCÏ„)</title>
          <description>OPC-108459 was administered as a 10-minute constant rate IV infusion. Blood samples were collected pre-dose (within 45 minutes of dosing), at the end of infusion and 0.5, 1, 2, 4, 8 and 24 hours post infusion.</description>
          <population>PK analysis dataset included all participants who had concentration time profiles consistent with proper intravenous infusion.</population>
          <units>Î¼gâˆ™h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.834"/>
                    <measurement group_id="O2" value="1.25">Due to only 1 participant with evaluable data.</measurement>
                    <measurement group_id="O3" value="2.10" spread="0.318"/>
                    <measurement group_id="O4" value="1.28" spread="0.388"/>
                    <measurement group_id="O5" value="1.68" spread="0.650"/>
                    <measurement group_id="O6" value="1.51" spread="0.651"/>
                    <measurement group_id="O7" value="2.79" spread="0.990"/>
                    <measurement group_id="O8" value="4.38" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1:Maximal Change From Baseline in QT Interval Corrected for Heart Rate Using the Fridericia Formula (QTcF) Within 24 Hour Infusion</title>
        <description>12-lead Holter monitors were placed on all participants within 45 minutes prior to dosing. Post dose measurements were made at 2, 4, 6, 8, 10, 20, 30, and 40 minutes and 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose. To achieve consistent recording, Holter sampling will be recorded with the participant recumbent and at rest for at least 10 minutes prior to collection.</description>
        <time_frame>24 hours</time_frame>
        <population>Safety dataset included all participants who had received at least one dose of the trial medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxysmal AF - OPC-108459 0.26 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 0.26 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O2">
            <title>Paroxysmal AF - OPC-108459 0.40 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 0.40 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O3">
            <title>Paroxysmal AF - OPC-108459 1.00 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 1.00 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O4">
            <title>Paroxysmal AF - Placebo</title>
            <description>Participants had received placebo dose 10-minute constant rate IV infusion.</description>
          </group>
          <group group_id="O5">
            <title>Persistent AF - OPC-108459 0.26 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 0.26 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O6">
            <title>Persistent AF - OPC-108459 0.40 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 0.40 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O7">
            <title>Persistent AF - OPC-108459 0.60 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 0.60 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O8">
            <title>Persistent AF - OPC-108459 1.35 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 1.35 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O9">
            <title>Persistent AF - OPC-108459 1.55 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 1.55 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O10">
            <title>Persistent AF - Placebo</title>
            <description>Participants had received a single dose of placebo, 10-minute constant rate IV infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1:Maximal Change From Baseline in QT Interval Corrected for Heart Rate Using the Fridericia Formula (QTcF) Within 24 Hour Infusion</title>
          <description>12-lead Holter monitors were placed on all participants within 45 minutes prior to dosing. Post dose measurements were made at 2, 4, 6, 8, 10, 20, 30, and 40 minutes and 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose. To achieve consistent recording, Holter sampling will be recorded with the participant recumbent and at rest for at least 10 minutes prior to collection.</description>
          <population>Safety dataset included all participants who had received at least one dose of the trial medication.</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="8.0"/>
                    <measurement group_id="O2" value="NA">Due to only 1 participant with evaluable data.</measurement>
                    <measurement group_id="O3" value="28.8" spread="12.0"/>
                    <measurement group_id="O4" value="11.5" spread="10.6"/>
                    <measurement group_id="O5" value="24.5" spread="21.4"/>
                    <measurement group_id="O6" value="24.0" spread="9.5"/>
                    <measurement group_id="O7" value="23.3" spread="20.2"/>
                    <measurement group_id="O8" value="19.7" spread="6.5"/>
                    <measurement group_id="O9" value="42.5" spread="29.0"/>
                    <measurement group_id="O10" value="27.4" spread="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.8" spread="7.8"/>
                    <measurement group_id="O2" value="NA">Due to only 1 participant with evaluable data.</measurement>
                    <measurement group_id="O3" value="-18.2" spread="7.8"/>
                    <measurement group_id="O4" value="-37.0" spread="8.5"/>
                    <measurement group_id="O5" value="-15.3" spread="9.6"/>
                    <measurement group_id="O6" value="-17.8" spread="14.1"/>
                    <measurement group_id="O7" value="-23.0" spread="6.5"/>
                    <measurement group_id="O8" value="-18.7" spread="16.5"/>
                    <measurement group_id="O9" value="-13.3" spread="14.0"/>
                    <measurement group_id="O10" value="-25.8" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Maximal Change From Baseline in Ventricular Rate Within 24 Hour Infusion</title>
        <description>12-lead Holter monitors were placed on all participants within 45 minutes prior to dosing. Post dose measurements were made at 2, 4, 6, 8, 10, 20, 30, and 40 minutes and 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose. To achieve consistent recording, Holter sampling will be recorded with the participant recumbent and at rest for at least 10 minutes prior to collection.</description>
        <time_frame>24 hours</time_frame>
        <population>Safety dataset included all participants who had received at least one dose of the trial medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxysmal AF - OPC-108459 0.26 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 0.26 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O2">
            <title>Paroxysmal AF - OPC-108459 0.40 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 0.40 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O3">
            <title>Paroxysmal AF - OPC-108459 1.00 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 1.00 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O4">
            <title>Paroxysmal AF - Placebo</title>
            <description>Participants had received placebo dose 10-minute constant rate IV infusion.</description>
          </group>
          <group group_id="O5">
            <title>Persistent AF - OPC-108459 0.26 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 0.26 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O6">
            <title>Persistent AF - OPC-108459 0.40 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 0.40 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O7">
            <title>Persistent AF - OPC-108459 0.60 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 0.60 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O8">
            <title>Persistent AF - OPC-108459 1.35 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 1.35 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O9">
            <title>Persistent AF - OPC-108459 1.55 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 1.55 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O10">
            <title>Persistent AF - Placebo</title>
            <description>Participants had received a single dose of placebo, 10-minute constant rate IV infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Maximal Change From Baseline in Ventricular Rate Within 24 Hour Infusion</title>
          <description>12-lead Holter monitors were placed on all participants within 45 minutes prior to dosing. Post dose measurements were made at 2, 4, 6, 8, 10, 20, 30, and 40 minutes and 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose. To achieve consistent recording, Holter sampling will be recorded with the participant recumbent and at rest for at least 10 minutes prior to collection.</description>
          <population>Safety dataset included all participants who had received at least one dose of the trial medication.</population>
          <units>beats/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3" spread="18.5"/>
                    <measurement group_id="O2" value="NA">Due to only 1 participant with evaluable data.</measurement>
                    <measurement group_id="O3" value="14.6" spread="5.0"/>
                    <measurement group_id="O4" value="15.5" spread="6.4"/>
                    <measurement group_id="O5" value="19.5" spread="9.1"/>
                    <measurement group_id="O6" value="18.5" spread="6.2"/>
                    <measurement group_id="O7" value="14.8" spread="13.1"/>
                    <measurement group_id="O8" value="28.0" spread="5.0"/>
                    <measurement group_id="O9" value="31.5" spread="15.6"/>
                    <measurement group_id="O10" value="26.0" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.3" spread="6.6"/>
                    <measurement group_id="O2" value="NA">Due to only 1 participant with evaluable data.</measurement>
                    <measurement group_id="O3" value="-29.8" spread="26.6"/>
                    <measurement group_id="O4" value="-24.0" spread="1.4"/>
                    <measurement group_id="O5" value="-6.8" spread="6.4"/>
                    <measurement group_id="O6" value="-12.3" spread="3.3"/>
                    <measurement group_id="O7" value="-19.8" spread="13.5"/>
                    <measurement group_id="O8" value="-11.5" spread="3.5"/>
                    <measurement group_id="O9" value="-8.3" spread="6.4"/>
                    <measurement group_id="O10" value="-12.4" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Maximal Change From Baseline in Blood Pressure Within 24 Hour Infusion</title>
        <description>Maximum change from baseline in diastolic and systolic blood pressure(BP) collected during vital sign measurements in the 24-hour postdose interval. Participants must be hemodynamically stable defined as a screening systolic blood pressure between 90 to 160 mmHg, diastolic &lt;100 mmHg. BP was measured after at least 3 minutes in the supine position. BP was measured at predose (within 45 minutes of dosing); 3 and 7 minutes and approximately 1, 4, 8, 12, and 24 hours.</description>
        <time_frame>24 hours</time_frame>
        <population>Safety dataset included all participants who had received at least one dose of the trial medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxysmal AF - OPC-108459 0.26 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 0.26 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O2">
            <title>Paroxysmal AF - OPC-108459 0.40 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 0.40 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O3">
            <title>Paroxysmal AF - OPC-108459 1.00 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 1.00 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O4">
            <title>Paroxysmal AF - Placebo</title>
            <description>Participants had received placebo dose 10-minute constant rate IV infusion.</description>
          </group>
          <group group_id="O5">
            <title>Persistent AF - OPC-108459 0.26 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 0.26 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O6">
            <title>Persistent AF - OPC-108459 0.40 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 0.40 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O7">
            <title>Persistent AF - OPC-108459 0.60 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 0.60 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O8">
            <title>Persistent AF - OPC-108459 1.35 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 1.35 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O9">
            <title>Persistent AF - OPC-108459 1.55 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 1.55 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O10">
            <title>Persistent AF - Placebo</title>
            <description>Participants had received a single dose of placebo, 10-minute constant rate IV infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Maximal Change From Baseline in Blood Pressure Within 24 Hour Infusion</title>
          <description>Maximum change from baseline in diastolic and systolic blood pressure(BP) collected during vital sign measurements in the 24-hour postdose interval. Participants must be hemodynamically stable defined as a screening systolic blood pressure between 90 to 160 mmHg, diastolic &lt;100 mmHg. BP was measured after at least 3 minutes in the supine position. BP was measured at predose (within 45 minutes of dosing); 3 and 7 minutes and approximately 1, 4, 8, 12, and 24 hours.</description>
          <population>Safety dataset included all participants who had received at least one dose of the trial medication.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diastolic BP Supine (Decrease)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.8" spread="11.4"/>
                    <measurement group_id="O2" value="NA">Due to only 1 participant with evaluable data.</measurement>
                    <measurement group_id="O3" value="-13.4" spread="8.7"/>
                    <measurement group_id="O4" value="-25.7" spread="18.3"/>
                    <measurement group_id="O5" value="-13.5" spread="15.3"/>
                    <measurement group_id="O6" value="-5.0" spread="4.2"/>
                    <measurement group_id="O7" value="-14.5" spread="9.3"/>
                    <measurement group_id="O8" value="-18.7" spread="24.6"/>
                    <measurement group_id="O9" value="-19.0" spread="6.2"/>
                    <measurement group_id="O10" value="-10.8" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP Supine (Increase)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="2.5"/>
                    <measurement group_id="O2" value="26.0">Due to only 1 participant with evaluable data.</measurement>
                    <measurement group_id="O3" value="18.6" spread="25.1"/>
                    <measurement group_id="O4" value="8.0" spread="11.3"/>
                    <measurement group_id="O5" value="5.3" spread="5.1"/>
                    <measurement group_id="O6" value="5.0" spread="2.6"/>
                    <measurement group_id="O7" value="1.7" spread="0.6"/>
                    <measurement group_id="O8" value="9.8" spread="7.9"/>
                    <measurement group_id="O9" value="21.0" spread="6.7"/>
                    <measurement group_id="O10" value="10.2" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic BP Supine (Decrease)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.3" spread="6.4"/>
                    <measurement group_id="O2" value="NA">Due to only 1 participant with evaluable data.</measurement>
                    <measurement group_id="O3" value="-20.8" spread="14.1"/>
                    <measurement group_id="O4" value="-18.3" spread="18.6"/>
                    <measurement group_id="O5" value="-7.8" spread="5.7"/>
                    <measurement group_id="O6" value="-3.0" spread="1.4"/>
                    <measurement group_id="O7" value="-9.0" spread="6.2"/>
                    <measurement group_id="O8" value="-17.3" spread="13.7"/>
                    <measurement group_id="O9" value="-24.5" spread="10.5"/>
                    <measurement group_id="O10" value="-23.0" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic BP Supine (Increase)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" spread="10.4"/>
                    <measurement group_id="O2" value="42.0">Due to only 1 participant with evaluable data.</measurement>
                    <measurement group_id="O3" value="16.6" spread="11.9"/>
                    <measurement group_id="O4" value="14.3" spread="23.1"/>
                    <measurement group_id="O5" value="7.5" spread="8.4"/>
                    <measurement group_id="O6" value="11.3" spread="8.2"/>
                    <measurement group_id="O7" value="8.5" spread="7.5"/>
                    <measurement group_id="O8" value="21.7" spread="6.4"/>
                    <measurement group_id="O9" value="15.0" spread="6.4"/>
                    <measurement group_id="O10" value="12.1" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2/1 Infusion: Cmax</title>
        <description>The trial was terminated after Part 1 enrollment completed. All analyses described in this document were performed on Part 1 data. However, Part 2 was not conducted and therefore is not included in this document.</description>
        <time_frame>24 hours</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2/2 Infusions: Cmax</title>
        <description>The trial was terminated after Part 1 enrollment completed. All analyses described in this document were performed on Part 1 data. However, Part 2 was not conducted and therefore is not included in this document.</description>
        <time_frame>24 hours</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2/1 Infusion: AUCt</title>
        <description>The trial was terminated after Part 1 enrollment completed. All analyses described in this document were performed on Part 1 data. However, Part 2 was not conducted and therefore is not included in this document.</description>
        <time_frame>24 hours</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2/2 Infusions: AUCt</title>
        <description>The trial was terminated after Part 1 enrollment completed. All analyses described in this document were performed on Part 1 data. However, Part 2 was not conducted and therefore is not included in this document.</description>
        <time_frame>24 hours</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: QTcF</title>
        <description>The trial was terminated after Part 1 enrollment completed. All analyses described in this document were performed on Part 1 data. However, Part 2 was not conducted and therefore is not included in this document.</description>
        <time_frame>24 hours</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Ventricular Rate</title>
        <description>The trial was terminated after Part 1 enrollment completed. All analyses described in this document were performed on Part 1 data. However, Part 2 was not conducted and therefore is not included in this document.</description>
        <time_frame>24 hours</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Diastolic and Systolic Blood Pressure</title>
        <description>The trial was terminated after Part 1 enrollment completed. All analyses described in this document were performed on Part 1 data. However, Part 2 was not conducted and therefore is not included in this document.</description>
        <time_frame>24 hours</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Percentage of Subjects With Normal Sinus Rhythm (NSR)</title>
        <description>The trial was terminated after Part 1 enrollment completed. All analyses described in this document were performed on Part 1 data. However, Part 2 was not conducted and therefore is not included in this document.</description>
        <time_frame>24 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Percentage of Participants With NSR</title>
        <description>Percent of participants with NSR, defined as NSR for at least 1 minute within 30 minutes of the end of OPC-108459 infusion.</description>
        <time_frame>30 minutes</time_frame>
        <population>Safety dataset included all participants who had received at least one dose of the trial medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxysmal AF - OPC-108459 0.26 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 0.26 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O2">
            <title>Paroxysmal AF - OPC-108459 0.40 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 0.40 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O3">
            <title>Paroxysmal AF - OPC-108459 1.00 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 1.00 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O4">
            <title>Paroxysmal AF - Placebo</title>
            <description>Participants had received placebo dose 10-minute constant rate IV infusion.</description>
          </group>
          <group group_id="O5">
            <title>Persistent AF - OPC-108459 0.26 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 0.26 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O6">
            <title>Persistent AF - OPC-108459 0.40 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 0.40 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O7">
            <title>Persistent AF - OPC-108459 0.60 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 0.60 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O8">
            <title>Persistent AF - OPC-108459 1.35 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 1.35 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O9">
            <title>Persistent AF - OPC-108459 1.55 mg/kg</title>
            <description>Participants had received a single dose of OPC-108459 1.55 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
          </group>
          <group group_id="O10">
            <title>Persistent AF - Placebo</title>
            <description>Participants had received a single dose of placebo, 10-minute constant rate IV infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Percentage of Participants With NSR</title>
          <description>Percent of participants with NSR, defined as NSR for at least 1 minute within 30 minutes of the end of OPC-108459 infusion.</description>
          <population>Safety dataset included all participants who had received at least one dose of the trial medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Time to NSR</title>
        <description>The trial was terminated after Part 1 enrollment completed. All analyses described in this document were performed on Part 1 data. However, Part 2 was not conducted and therefore is not included in this document.</description>
        <time_frame>24 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Duration of NSR</title>
        <description>The trial was terminated after Part 1 enrollment completed. All analyses described in this document were performed on Part 1 data. However, Part 2 was not conducted and therefore is not included in this document.</description>
        <time_frame>24 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Duration of NSR</title>
        <description>The trial was terminated after Part 1 enrollment completed. All analyses described in this document were performed on Part 1 data. However, Part 2 was not conducted and therefore is not included in this document.</description>
        <time_frame>168 hours</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported from the signing of the informed consent throughout the 8-day study until the final follow-up phone call Day 31 (+2) days post dose.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Paroxysmal AF - OPC-108459 0.26 mg/kg</title>
          <description>Participants had received a single dose of OPC-108459 0.26 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
        </group>
        <group group_id="E2">
          <title>Paroxysmal AF - OPC-108459 0.40 mg/kg</title>
          <description>Participants had received a single dose of OPC-108459 0.40 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
        </group>
        <group group_id="E3">
          <title>Paroxysmal AF - OPC-108459 1.00 mg/kg</title>
          <description>Participants had received a single dose of OPC-108459 1.00 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
        </group>
        <group group_id="E4">
          <title>Paroxysmal AF - Placebo</title>
          <description>Participants had received placebo dose 10-minute constant rate IV infusion.</description>
        </group>
        <group group_id="E5">
          <title>Persistent AF - OPC-108459 0.26 mg/kg</title>
          <description>Participants had received a single dose of OPC-108459 0.26 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
        </group>
        <group group_id="E6">
          <title>Persistent AF - OPC-108459 0.40 mg/kg</title>
          <description>Participants had received a single dose of OPC-108459 0.40 mg/kg,10-minute constant rate IV infusion to achieve specified Cmax target.</description>
        </group>
        <group group_id="E7">
          <title>Persistent AF - OPC-108459 0.60 mg/kg</title>
          <description>Participants had received a single dose of OPC-108459 0.60 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
        </group>
        <group group_id="E8">
          <title>Persistent AF - OPC-108459 1.35 mg/kg</title>
          <description>Participants had received a single dose of OPC-108459 1.35 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
        </group>
        <group group_id="E9">
          <title>Persistent AF - OPC-108459 1.55 mg/kg</title>
          <description>Participants had received a single dose of OPC-108459 1.55 mg/kg, 10-minute constant rate IV infusion to achieve specified Cmax target.</description>
        </group>
        <group group_id="E10">
          <title>Persistent AF - Placebo</title>
          <description>Participants had received a single dose of placebo, 10-minute constant rate IV infusion.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Major Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sinus arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Intra-abdominal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial was terminated after Part 1 enrollment completed. It did not progress due to many factors including slow enrollment, limited site activity in pre-screening, absence of reproducible efficacy signal and increased costs.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Global Medical Affairs</name_or_title>
      <organization>Otsuka Pharmaceutical Development and Commercialization, Inc.</organization>
      <phone>800 562-3974</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

